FDA cleared an Investigational New Drug (IND) application for a Phase 1/2 study of an oral tablet formulation of elraglusib. The study aims to demonstrate that the oral formulation achieves higher drug exposure compared to the previous IV formulation. Clinical development for the oral program is scheduled to initiate in the second half of 2026. The company is targeting indications including metastatic melanoma, NSCLC, colorectal, and pancreatic cancers. Martin Huber, MD, has been appointed to the Board of Directors to support strategic growth.